These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25473914)

  • 1. IL-18 is not therapeutic for neovascular age-related macular degeneration.
    Hirano Y; Yasuma T; Mizutani T; Fowler BJ; Tarallo V; Yasuma R; Kim Y; Bastos-Carvalho A; Kerur N; Gelfand BD; Bogdanovich S; He S; Zhang X; Nozaki M; Ijima R; Kaneko H; Ogura Y; Terasaki H; Nagai H; Haro I; Núñez G; Ambati BK; Hinton DR; Ambati J
    Nat Med; 2014 Dec; 20(12):1372-5. PubMed ID: 25473914
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration.
    Doyle SL; Adamson P; López FJ; Humphries P; Campbell M
    Nat Med; 2014 Dec; 20(12):1376-7. PubMed ID: 25473915
    [No Abstract]   [Full Text] [Related]  

  • 3. Eye diseases: a new use for interleukin-18 in sight.
    Bray N
    Nat Rev Drug Discov; 2014 Jun; 13(6):418. PubMed ID: 24833293
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration.
    Doyle SL; Ozaki E; Brennan K; Humphries MM; Mulfaul K; Keaney J; Kenna PF; Maminishkis A; Kiang AS; Saunders SP; Hams E; Lavelle EC; Gardiner C; Fallon PG; Adamson P; Humphries P; Campbell M
    Sci Transl Med; 2014 Apr; 6(230):230ra44. PubMed ID: 24695684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches for vision loss due to choroidal neovascularizations in age related macular degeneration.
    Costagliola C
    Curr Drug Targets; 2011 Feb; 12(2):133-7. PubMed ID: 20887248
    [No Abstract]   [Full Text] [Related]  

  • 6. Towards a rational approach to combination therapy for neovascular age-related macular degeneration.
    Arroyo JG
    Br J Ophthalmol; 2007 Feb; 91(2):130-1. PubMed ID: 17244655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A very effective treatment for neovascular macular degeneration.
    Stone EM
    N Engl J Med; 2006 Oct; 355(14):1493-5. PubMed ID: 17021326
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of photodynamic treatment of choroidal neovascular membrane in age-related macular degeneration].
    Dubská Z; Kalvodová B
    Cas Lek Cesk; 2006; 145(10):800, 802-3. PubMed ID: 17121073
    [No Abstract]   [Full Text] [Related]  

  • 9. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration.
    Fine SL
    Arch Ophthalmol; 1999 Oct; 117(10):1400-2. PubMed ID: 10532450
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravitreal therapy in bilateral neovascular age-related macular degeneration.
    Barthelmes D; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Campain A; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Ophthalmology; 2014 Oct; 121(10):2073-4. PubMed ID: 24939512
    [No Abstract]   [Full Text] [Related]  

  • 11. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration.
    Falavarjani KG; Sadda SR
    Curr Pharm Des; 2017; 23(4):535-541. PubMed ID: 27981904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Therapeutic Conversation and a Holistic Approach to the Management of Patients with Neovascular Age-Related Macular Degeneration.
    Cackett PD; Young SL
    Ophthalmologica; 2022; 245(4):393-394. PubMed ID: 35477167
    [No Abstract]   [Full Text] [Related]  

  • 13. [Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration].
    Bartz-Schmidt KU; Holz FG
    Ophthalmologe; 2006 Jun; 103(6):461-2. PubMed ID: 16763861
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing neovascular age-related macular degeneration: a step into the light.
    Guymer RH
    Med J Aust; 2007 Mar; 186(6):276-7. PubMed ID: 17371204
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
    Kumar A; Sahni JN; Stangos AN; Campa C; Harding SP
    Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy.].
    Pauleikhoff D; Kirchhof B; Bertram B; Holz FG; Bartz-Schmidt UB; Bornfeld N; Bresgen M; Heimann H; Helbig H; Hörauf H; Kampik A; Lemmen KD; Roider J
    Ophthalmologe; 2011 Jan; 108(1):85-90. PubMed ID: 21253745
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 18. Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD).
    Sharma A; Kumar N; Parachuri N; Sharma R; Bandello F; Kuppermann BD; Regillo CD
    Eye (Lond); 2020 Aug; 34(8):1310-1312. PubMed ID: 32132677
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary: Patterns of treatment discontinuation in neovascular age-related macular degeneration.
    Pai A
    Indian J Ophthalmol; 2022 Jun; 70(6):2070-2071. PubMed ID: 35647984
    [No Abstract]   [Full Text] [Related]  

  • 20. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice.
    Michalova K; Wickremasinghe SS; Tan TH; Chang A; Harper CA; Downie JA; Hunyor AP; Guymer RH
    Eye (Lond); 2009 Aug; 23(8):1633-40. PubMed ID: 19648888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.